Companies: 10,795·Total market cap: $144.5T
AbCellera Biologics Inc.

AbCellera Biologics Inc.

ABCLNASDAQHealthcare● Active
$5.62
$-0.75(-11.77%)
Market Cap$1.7B
P/E Ratio—
52W High$6.79
52W Low$2.33
Overview
Stock ranking:Biotechnology·Healthcare·View All Market Cap Rankings →

AbCellera Biologics Inc. (ABCL) Stock Overview

Key statistics and deep links to earnings, valuation, revenue, dividends, and more.

FMP · ABCL · as of Jun 8, 2026

Key Statistics

EPS (TTM)$-0.48abcl eps ttm · abcl earnings per shareEarnings history
PE Ratio (TTM)—abcl pe ratio ttm · abcl price to earningsPE Ratio deep dive
Revenue (TTM)$79.2Mabcl revenue ttm · abcl annual revenueFull revenue history
Dividend YieldNo Dividenddoes abcl pay dividends · abcl dividend yieldDividend history
Shares Outstanding298.7Mabcl shares outstanding · abcl floatShares outstanding history
Next EarningsAug 6, 2026Est.abcl earnings date · abcl next earningsEarnings history

Explore AbCellera Biologics Inc. Data

abcl stock data · financials
Market Cap$1.7Babcl market cap · abcl valuation
Analyst Forecast$8 · Buy
DividendsNo Dividenddoes abcellera biologics inc. pay dividends · abcl dividend yield
Revenue$75.1M+160.56%abcellera biologics inc. annual revenue · abcl revenue
EarningsEPS $-0.49+10.91%abcl earnings · abcl eps
PE Ratio—abcl pe ratio · abcl price to earnings

Financial Snapshot

Full Financials
FY 2025Revenue$75.1M▲ +160.56% YoY
202320242025
abcellera biologics inc. revenue · abcl revenue 2025
FY 2025Net Income-$146.4M▲ +10.10% YoY
202320242025
abcellera biologics inc. net income · abcl profit 2025
FY 2025EPS$-0.49▲ +10.91% YoY
202320242025
abcl eps · abcellera biologics inc. earnings per share 2025
TTM:Revenue: $79.2MNet Income: -$144.0MEPS: $-0.48View income statement →

Analyst Ratings & Price Target

Full Forecast
SellBuy
Buy11 analystsis abcl a buy · abcl analyst rating
Strong Buy
0
Buy
9
Hold
2
Sell
0
Strong Sell
0
12-Month Price Target
$7.00Low
$5.62Current
$7.50Avg Target33.45% upside
$8.00High
abcl price target · abcl 12 month forecast

Total: 11 · Buy rate: 81.8%

The ABCL analyst consensus is Buy, based on ratings from 11 Wall Street analysts over the past 3 months. The average 12-month price target is $7.50, representing +33.45% upside from the current price of $5.62.

Stock Performance

Full History
1D-11.77%
1W-6.49%
1M+7.25%
3M+62.90%
YTD+64.33%
1Y+123.90%
5Y-77.50%

About AbCellera Biologics Inc.

CEOCarl Hansen
IPO DateDec 11, 2020
Employees596
CountryCA
Websiteabcellera.com

AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems …

BiotechnologyHealthcareNASDAQCA

what is abcellera biologics inc. · abcl stock overview · abcellera biologics inc. company profile · who is abcellera biologics inc. ceo · abcl NASDAQ · abcellera biologics inc. headquarters · abcellera biologics inc. business segments

About Stock Overview & Key Data

AbCellera Biologics Inc. (ABCL) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Dec 11, 2020. As of the latest trading session, ABCL stock price is $5.62, with a market capitalization of $1.7B. The stock has returned +123.90% over the past 12 months and +64.33% year-to-date.

According to 11 Wall Street analysts, the consensus rating for AbCellera Biologics Inc. stock is Buy, with an average 12-month price target of $7.50. In fiscal year 2025, AbCellera Biologics Inc. reported revenue of $75.1M and net income of -$146.4M. For detailed data — including AbCellera Biologics Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.

Frequently Asked Questions

As of the latest trading session, AbCellera Biologics Inc. (ABCL) stock price is $5.62. The stock is traded on NASDAQ under the ticker symbol ABCL. The 52-week range is $2.33 – $6.79.

ABCL stock priceABCL quote todaylive ticker
Data provided by Financial Modeling PrepLast updated: Jun 8, 2026Not investment advice